Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online

BACKGROUND: Due to high survival rates and the relatively small benefit of adjuvant therapy, the application of personalized medicine (PM) through risk stratification is particularly beneficial in early breast cancer (BC) to avoid unnecessary harms from treatment. The new 21-gene assay (OncotypeDX,...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BMC Cancer
Asıl Yazarlar: Jahn, Beate, Rochau, Ursula, Kurzthaler, Christina, Hubalek, Michael, Miksad, Rebecca, Sroczynski, Gaby, Paulden, Mike, Bundo, Marvin, Stenehjem, David, Brixner, Diana, Krahn, Murray, Siebert, Uwe
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2017
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5644100/
https://ncbi.nlm.nih.gov/pubmed/29037213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3603-z
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller